דוסיטקסל טבע ® 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

DOCETAXEL 27.73 MG / 1 ML

Pieejams no:

ABIC MARKETING LTD

ATĶ kods:

L01CD02

Zāļu forma:

CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

Ievadīšanas:

I.V

Ražojis:

PHARMACHEMIE B.V., THE NETHERLANDS

Ārstniecības grupa:

DOCETAXEL

Ārstēšanas norādes:

Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have inclu

Autorizācija datums:

2011-06-01